Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER
Background Thromboprophylaxis extended after hospital discharge in medically ill patients currently is not recommended by practice guidelines because of uncertainty about the benefit for preventing major or fatal thromboembolic events, and the risk of bleeding. Methods and Results We assessed the be...
Guardado en:
Autores principales: | Gary E. Raskob, Alex C. Spyropoulos, Theodore E. Spiro, Wentao Lu, Zhong Yuan, Bennett Levitan, Eunyoung Suh, Elliot S. Barnathan |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b3ae24eeae734c9d9ca797881cf8076b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
EVALUATION OF EFFICIENCY AND SAFETY OF THROMBOPROPHYLAXIS AFTER ORTHOPEDIC OPERATIONS
por: A. V. Vybivantseva, et al.
Publicado: (2012) -
Equivalent VTE rates after total joint arthroplasty using thromboprophylaxis with aspirin versus potent anticoagulants: retrospective analysis of 4562 cases across a diverse healthcare system
por: Chelsea Matzko, et al.
Publicado: (2021) -
Rivaroxaban in acute venous thromboembolism: UK prescribing experience
por: Victoria Speed, et al.
Publicado: (2021) -
Thromboprophylaxis Measures to Prevent Venous Thromboembolism in Hospitalized Patients
por: Dilceu Silveira Tolentino Júnior, et al.
Publicado: (2020) -
Rivaroxaban triggered multifocal intratumoral hemorrhage of the cabozantinib-treated diffuse brain metastases: A case report and review of literature
por: Chen Luyue, et al.
Publicado: (2021)